40 YAŞ ALTI VE 55 YAŞ ÜSTÜ MEME KANSERLİ KADINLARIN KLİNİKOPATOLOJİK VE RADYOLOJİK BULGULARININ SAĞ KALIM ÜZERİNE ETKİLERİNİN KARŞILAŞTIRILMASI
Amaç
Meme kanserli kadınların tümörleri, yaşla birlikte gelişen
hormonal değişikliklere bağlı olarak klinik ve
biyolojik farklılıklar göstermektedir. Bu nedenle bu
çalışmada meme kanserli hastaların <40 yaş ve ≥55
yaşlarının radyolojik ve klinikopatolojik özelliklerini
karşılaştırdık.
Gereç ve Yöntem
10 yıllık dönemde üç merkezde meme kanseri nedeniyle
opere edilen 40 yaş altı 92 hasta ve 55 yaş
ve üzeri 322 hasta olmak üzere toplam 759 hastanın
dosyaları geriye dönük olarak incelendi ve Östrojen
Reseptör (ER), Progesteron Reseptör (PR), İnsan
Epidermal Büyüme Faktörü 2 (HER2) ,Lenfovaskuler
İnvazyon ( LVI ) durumu, Aksiller Lenf Nodu Metastazı
(ALNM) varlığı, multifokalite, Duktal Karsinoma
İnsitu (DCIS) veya Lobuler Karsinoma İnsitu (LCIS)
varlığı, tümör boyutu, tümör histopatolojik tipi, tümör
derecesi ve skoru kaydedildi.
Bulgular
40 yaşın altındaki hastalarda tümörün memenin üst-iç
ve alt-iç kadranlarında daha az yerleştiği, multifokalitenin
ise daha sık görüldüğü, büyük bir çoğunluğunun
dens meme yapısına sahip olduğu, tümörün histolojik
derecesinin yüksek olduğu, LVI ve LNM’nin daha
sık görüldüğü, daha düşük ER reseptör pozitifliği ve
daha yüksek Ki-67 proliferasyon indeksine sahip olduğu
saptandı (sırasıyla p<0.001, p<0.001, p<0.001,
p<0.001, p=0.021, p=0.039, p=0.001 ve p<0.001).
55 yaşının altındaki hastalarda tümörlerde multifokalitenin
ve meme dokusunun yoğunluğunun daha az
olduğu görüldü (sırasıyla p=0.002, p<0.001). 40 yaş
altı hastalarda moleküler alt tiplerden luminal B ve
TN daha fazla görülürken 55 yaş üzeri hastalarda luminal
A alt tipi daha fazla görüldü (sırasıyla p<0.001,
p=0.001).
Sonuç
<40 yaş ile 55 yaş ve üzeri hastalar arasında klinikopatolojik
farklılıklar doğrulandı. 40 yaşın altındaki
hastalarda meme kanseri için olumsuz prognostik
faktörler ortaya çıktı.
COMPARISON OF THE EFFECTS OF CLINICOPATHOLOGICAL AND RADIOLOGICAL FINDINGS ON SURVIVAL IN WOMEN YOUNGER THAN 40 YEARS AND OLDER THAN 55 YEARS OF AGE WITH BREAST CANCER
Objective
Tumors of women with breast cancer show clinical
and biological differences depending on the hormonal
changes that develop with age. Therefore, in this study,
we compared the radiologic, and clinicopathological
features of breast cancer patient’s < 40 age and ≥55
age.
Material and Method
The files of a total of 759 patients, including 92
patients under 40 aged, and 322 patients 55 aged and
over who were operated on for breast cancer over a
10-year period in three centres were retrospectively
reviewed and Estrojen Reseptor (ER), Progesteron
Reseptor (PR), Human epidermal growth factor
receptor 2 (HER2), Lymphovascular invasion (LVI)
status, presence of axillary lymph node metastasis
(ALNM), multifocality, presence of Ductal Carsinoma
İnsitu (DCIS) or Lobular Carsinoma İnsitu (LCIS),
tumor size, tumor histopathological type, grade, and
score were recorded.
Results
In patients under the age of 40, the tumor is less
localized in the upper-inner and lower-inner quadrants
of the breast, multifocality is more common, most of
them have dense breast structure, the histological
grade of the tumor is higher, LVI and LNM are more
common. It was found that they had ER receptor
positivity and higher Ki-67 proliferation index (p<0.001,
p<0.001, p<0.001, p<0.001, p=0.021, p=0.039,
p=0.001 and p<0.001, respectively). It was observed
that the multifocality and density of breast tissue were
lower in tumors in patients under 55 years of age (p =
0.002, p <0.001, respectively). Luminal B and TN were
more common among molecular subtypes in patients
under 40 years of age, while luminal A subtype
was more common in patients over 55 years of age
(p<0.001, p=0.001, respectively).
Conclusion
Clinicopathological differences between <40 aged,
and 55 aged and over patients were confirmed.
Adverse prognostic factors for breast cancer at the
age of under 40 patients were revealed.
___
- 1. Centers for Disease Control and Prevention (CDC). 2020. Breast
Cancer Statistics 2017. Retrieved from https://gis.cdc.gov/
Cancer/USCS/DataViz.html.
- 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal
A. Global cancer statistics 2018: GLOBOCAN estimates of incidence
and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018;68(6):394-424.
- 3. Thorat MA, Balasubramanian R. Breast cancer prevention
in high-risk women. Best Pract Res Clin Obstet Gynaecol.
2020;65:18-31.
- 4. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk
Factors and Preventions of Breast Cancer. Int J Biol Sci.
2017;13(11):1387-97.
- 5. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive
analysis of estrogen receptor (ER)-negative, progesterone
receptor (PR)-negative, and HER2-negative invasive
breast cancer, the so-called triple-negative phenotype: a population-
based study from the California cancer Registry. Cancer.
2007;109(9):1721-8.
- 6. Öztürk VS, Polat YD, Soyder A, Tanyeri A, Karaman CZ, Taşkın
F. The Relationship Between MRI Findings and Molecular Subtypes
in Women With Breast Cancer. Curr Probl Diagn Radiol.
2020;49(6):417-21.
- 7. Morkavuk ŞB, Güner M, Çulcu S, Eroğlu A, Bayar S, Ünal
AE. Relationship between lymphovascular invasion and molecular
subtypes in invasive breast cancer. Int J Clin Pract.
2020;6:e13897.
- 8. Pourteimoor V, Mohammadi-Yeganeh S, Paryan M. Breast cancer
classification and prognostication through diverse systems
along with recent emerging findings in this respect; the dawn
of new perspectives in the clinical applications. Tumour Biol.
2016;37(11):14479-99.
- 9. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer.
Adv Anat Pathol. 2020;27(1):27-35.
- 10. Kocaöz S, Korukluoğlu B, Parlak Ö, Doğan HT, Erdoğan F. Comparison
of clinicopathological features and treatments between
pre- and postmenopausal female breast cancer patients - a retrospective
study. Prz Menopauzalny. 2019;18(2):68-73.
- 11. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL,
Badve S, et al. American Society of Clinical Oncology/College
Of American Pathologists guideline recommendations for immunohistochemical
testing of estrogen and progesterone receptors
in breast cancer. J Clin Oncol. 2010;28(16):2784-95.
- 12. Sisti A, Huayllani MT, Boczar D, Restrepo DJ, Spaulding
AC, Emmanuel G, et al. Breast cancer in women: a descrip-
tive analysis of the national cancer database. Acta Biomed.
2020;91(2):332-41.
- 13. Han Y, Moore JX, Langston M, Fuzzell L, Khan S, Lewis MW, et
al. Do breast quadrants explain racial disparities in breast cancer
outcomes? Cancer Causes Control. 2019;30(11):1171-82.
- 14. Sohn VY, Arthurs ZM, Sebesta JA, Brown TA. Primary tumor
location impacts breast cancer survival. Am J Surg.
2008;195(5):641-4.
- 15. Shahar KH, Buchholz TA, Delpassand E, Sahin AA, Ross MI,
Ames FC, et al. Lower and central tumor location correlates with
lymphoscintigraphy drainage to the internal mammary lymph
nodes in breast carcinoma. Cancer. 2005;103(7):1323-9.
- 16. Zhang M, Wu K, Zhang P, Wang M, Bai F, Chen H. Breast-Conserving
Surgery is Oncologically Safe for Well-Selected, Centrally
Located Breast Cancer. Ann Surg Oncol. 2021;28(1):330-9.
- 17. Kocic B, Filipovic S, Vrbic V, Pejcic I. Breast cancer in women
under 40 years of age. J BUON. 2011;16(4):635-9.
- 18. Fried G, Kuten A, Dedia S, Borovik R, Robinson E. Experience
with conservative therapy in primary breast cancer: experiences
Northern Israel Oncology Center, 1981-1990. Harefuah.
1996;130(9):589-93, 654.
- 19. Foxcroft LM, Evans EB, Porter AJ. The diagnosis of breast cancer
in women younger than 40. Breast. 2004;13(4):297-306.
- 20. Appleton DC, Hackney L, Narayanan S. Ultrasonography alone
for diagnosis of breast cancer in women under 40. Ann R Coll
Surg Engl. 2014;96(3):202-6.
- 21. Durhan G, Azizova A, Önder Ö, Kösemehmetoğlu K, Karakaya
J, Akpınar MG, et al. Imaging Findings and Clinicopathological
Correlation of Breast Cancer in Women under 40 Years Old. Eur
J Breast Health. 2019;15(3):147-52.
- 22. Muttarak M, Pojchamarnwiputh S, Chaiwun B. Breast cancer in
women under 40 years: preoperative detection by mammography.
Ann Acad Med Singap. 2003;32(4):433-7.
- 23. Schnejder-Wilk A. Breast cancer imaging: Mammography
among women of up to 45 years. Pol J Radiol. 2010;75(1):37-
42.
- 24. Checka CM, Chun JE, Schnabel FR, Lee J, Toth H. The relationship
of mammographic density and age: implications for breast
cancer screening. AJR Am J Roentgenol. 2012;198(3):W292-5.
- 25. Liao YS, Zhang JY, Hsu YC, Hong MX, Lee LW. Age-Specific
Breast Density Changes in Taiwanese Women: A Cross-Sectional
Study. Int J Environ Res Public Health. 2020;17(9):3186.
- 26. Erić I, Petek Erić A, Koprivčić I, Babić M, Pačarić S, Trogrlić B.
Independent factors FOR poor prognosis in young patients with
stage I-III breast cancer. Acta Clin Croat. 2020;59(2):242-51.
- 27. Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, Fihri M, Hassani
S, et al. Clinicopathologic and prognostic features of breast
cancer in young women: a series from North of Morocco. BMC
Womens Health. 2017;17(1):106.
- 28. Tvedskov TF, Jensen MB, Lisse IM, Ejlertsen B, Balslev E, Kroman
N. High risk of non-sentinel node metastases in a group
of breast cancer patients with micrometastases in the sentinel
node. Int J Cancer. 2012;131(10):2367-75.
- 29. Eugênio DS, Souza JA, Chojniak R, Bitencourt AG, Graziano L,
Souza EF. Breast cancer features in women under the age of 40
years. Rev Assoc Med Bras (1992). 2016;62(8):755-61.
- 30. Wang JM, Wang J, Zhao HG, Liu TT, Wang FY. Reproductive
Risk Factors Associated with Breast Cancer Molecular Subtypes
among Young Women in Northern China. Biomed Res Int.
2020;2020:5931529.
- 31. Erić I, Petek Erić A, Kristek J, Koprivčić I, Babić M. Breast cancer
in young women: pathologic and immunohistochemical features.
Acta Clin Croat. 2018;57(3):497-502.
- 32. Han W, Kim SW, Park IA, Kang D, Kim SW, Youn YK, et al.
Young age: an independent risk factor for disease-free survival
in women with operable breast cancer. BMC Cancer. 2004;4:82.